Contact
Please use this form to send email to PR contact of this press release:
PhaseBio Announces Positive Results From Phase 1 Clinical Trial of PB2452, a Novel Reversal Agent for Ticagrelor
TO:
Please use this form to send email to PR contact of this press release:
PhaseBio Announces Positive Results From Phase 1 Clinical Trial of PB2452, a Novel Reversal Agent for Ticagrelor
TO: